454482-12-3 Usage
Description
4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by the presence of a methylated piperidine moiety attached to an aniline group, which contributes to its unique chemical properties and reactivity.
Uses
Used in Pharmaceutical Industry:
4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE is used as a precursor in the preparation of pyridopyrimidinones, which are a class of compounds with anti-inflammatory properties. These pyridopyrimidinones act as macrophage colony-stimulating factor-1 receptor inhibitors, playing a crucial role in modulating the immune response and reducing inflammation.
Additionally, 4-(1-METHYL-PIPERIDIN-4-YL)-ANILINE is utilized in the development of pharmacokinetic studies, which focus on understanding the absorption, distribution, metabolism, and excretion of drugs in the body. This knowledge is essential for optimizing drug efficacy and minimizing side effects, ultimately leading to the development of safer and more effective medications.
Check Digit Verification of cas no
The CAS Registry Mumber 454482-12-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,4,4,8 and 2 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 454482-12:
(8*4)+(7*5)+(6*4)+(5*4)+(4*8)+(3*2)+(2*1)+(1*2)=153
153 % 10 = 3
So 454482-12-3 is a valid CAS Registry Number.
InChI:InChI=1/C12H18N2/c1-10-6-8-14(9-7-10)12-4-2-11(13)3-5-12/h2-5,10H,6-9,13H2,1H3
454482-12-3Relevant articles and documents
BICYCLIC KINASE INHIBITORS AND USES THEREOF
-
, (2021/11/06)
The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.